Interleukin-17 Inhibitors and Early Major Adverse Cardiovascular Events

On the basis of previous studies and mechanistic models, concerns have been raised about the occurrence of major adverse cardiovascular events (MACEs) following the initiation of interleukin (IL)-17(R)A inhibitors in the setting of psoriasis and psoriatic arthritis.In a case–time-control analysis based on the French National Health Insurance database and including 34 241 individuals who received an IL-17(R)A inhibitor from 2016 to 2021, no statistically significant association was found between the initiation of IL-17(R)A inhibitors and the occurrence of MACEs in the following 6 months, using tumor necrosis factor-α inhibitors as active comparators.No significant association was found between MACEs and the initiation of IL-17(R)A inhibitors; however, a modest risk increase cannot be entirely ruled out.

Corresponding Author: Florence Poizeau, MD, PhD, Department of Dermatology, CHU Rennes, 2 Rue Henri le Guilloux 35000 Rennes, France (florence.poizeau@chu-rennes.fr).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.